1.Research progress on small molecule inhibitors of coronaviruses
Zhengguang YAO ; Zhibin WANG ; Chunnian XIA ; Chunlin ZHUANG
Journal of Pharmaceutical Practice 2020;38(5):385-397
Coronavirus infection seriously threatens human health. There is no specific medication or vaccine so far. In recent years, domestic and foreign researchers have developed a variety of small-molecule inhibitors against the ligand S protein, RdRp, PLpro and 3CLpro of three highly pathogenic coronavirus, SARS-CoV,MERS-CoV,SARS-CoV-2. This article reviews the characteristics of these coronaviruses, action targets, small molecule inhibitors, and structure-activity relationships.
2.Cytotoxicity study on FC58, an indole-chalcone, against multi-drug resistant leukemia cells
Jiawei DAI ; Saijian SHI ; Aiwei SONG ; Zhibin WANG ; Chunlin ZHUANG ; Chunnian XIA
Journal of Pharmaceutical Practice 2021;39(4):305-308
Objective To synthesize and investigate cytotoxicity of an indole-chalcone derivative FC58. Methods The target compound was synthesized through the Aldol condensation with 1-(3,4,5-trimethoxyphenyl)ethan-1-one and 1H-indole-3-carbaldehyde. The Cell Titer-Blue method was used to determine in vitro cytotoxicity. The cell cycle experiment was performed to analyze the action characteristics of FC58. Results FC58 exhibited high cytotoxicity against various leukemia cells and resulted in G2/M phase arrest. It showed stronger drug resistant index than traditional tubulin inhibitors such as paclitaxel, vinblastine and doxorubicin. Conclusion FC58 represents a promising lead compound for multi-drug resistant leukemia.